IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A monoclonal antibody, ~~characterized by reacting strongly with uracil and thymine but scarcely with N-carbamyl-β-alanine~~ which exhibits a selectivity in cross reaction with N-carbamyl-β-alanine of 10% or less, when the selectivity in cross reaction with uracil or thymine is 90% or more.

Claim 2 (Currently Amended): ~~A~~ The monoclonal antibody ~~as described in~~ of claim 1, which exhibits ~~scarce or~~ low reactivity with pseudouridine, dihydrouracil, and dihydrothymine.

Claim 3 (Canceled).

Claim 4 (Currently Amended): ~~A~~ The monoclonal antibody ~~as described in~~ of claim 1 ~~or 3~~, which exhibits a selectivity in cross reaction with N-carbamyl-β-alanine of 10% or less; a selectivity in cross reaction with pseudouridine of 33% or less; a selectivity in cross reaction with dihydrouracil of 8% or less; and a selectivity in cross reaction with dihydrothymine of 23% or less; when the selectivity in cross reaction with uracil or thymine is 90% or more.

Claim 5 (Currently Amended): ~~A~~ The monoclonal antibody as described ~~in any one of claims 1 to 4~~ of claim 1, which is produced from a hybridoma which is formed from a myeloma cell and an antibody-producing cell derived from an animal to which 5-halogeno-1-carboxymethyluracil has been administered.

Claim 6 (Currently Amended): ~~A~~ The monoclonal antibody as described in claim 5, wherein the hybridoma is FERM BP-6870 ~~strain~~.

Claim 7 (Currently Amended): A hybridoma producing ~~a~~ the monoclonal antibody ~~asrecited in any one of claims 1 to 6~~ of claim 1.

Claim 8 (Currently Amended): A method for immunochemically assaying uracil and thymine ~~by use of a monoclonal antibody as recited in any one of claims 1 to 6~~ comprising contacting a sample possibly containing uracil and thymine with the monoclonal antibody of claim 1; and

detecting the formation of an antibody-antigen complex, wherein the presence of the antibody-antigen complex is indicative of the presence of uracil and thymine in the sample.

Claim 9 (Currently Amended): A ~~diagnostic agent for diagnosing DPD deficiency~~ composition, ~~which agent contains a~~ comprising the monoclonal antibody ~~as recited in any one of claims 1 to 6~~ of claim 1; and a carrier.

Claim 10 (Currently Amended): A method for diagnosing DPD deficiency in an individual, ~~characterized by assaying uracil and thymine in a specimen by use of a diagnostic agent for diagnosing DPD deficiency as recited in claim 9~~ comprising, assaying uracil and thymine according to the method of claim 8, wherein the sample is obtained from the individual and wherein the presence of uracil and thymine in the sample is diagnostic for DPD deficiency in the individual.

Claim 11 (Canceled).

Claim 12 (New): A hybridoma producing the monoclonal antibody of claim 4.

Claim 13 (New): A method for immunochemically assaying uracil and thymine comprising contacting a sample possibly containing uracil and thymine with the monoclonal antibody of claim 4; and

detecting the formation of an antibody-antigen complex, wherein the presence of the antibody-antigen complex is indicative of the presence of uracil and thymine in the sample.

Claim 14 (New): A composition, comprising the monoclonal antibody of claim 4; and a carrier.

Claim 15 (New): A method for diagnosing DPD deficiency in an individual, comprising, assaying uracil and thymine according to the method of claim 13, wherein the sample is obtained from the individual and wherein the presence of uracil and thymine in the sample is diagnostic for DPD deficiency in the individual.

Claim 16 (New): A hybridoma producing the monoclonal antibody of claim 6.

Claim 17 (New): A method for immunochemically assaying uracil and thymine comprising contacting a sample possibly containing uracil and thymine with the monoclonal antibody of claim 6; and

detecting the formation of an antibody-antigen complex, wherein the presence of the antibody-antigen complex is indicative of the presence of uracil and thymine in the sample.

Claim 18 (New): A composition, comprising the monoclonal antibody of claim 6; and a carrier.

Claim 19 (New): A method for diagnosing DPD deficiency in an individual, comprising, assaying uracil and thymine according to the method of claim 17, wherein the sample is obtained from the individual and wherein the presence of uracil and thymine in the sample is diagnostic for DPD deficiency in the individual.